Upgrade: "now believes Forest Labs will be able to resolve its Bystolic litigation with all generic challengers and views its respiratory franchise as undervalued."
Now Believe ... Will Be Able to Resolve ...!!!
Word Game! The Key Word is "RESOLVE", i.e., will be able to have resolutions. Even a lost is a resolution.
"Respiratory franchise ... undervalued"!!!!
COPD is a tricky field. Available treatments usually are with weak efficacy and serious side effects. The primary cause of serious COPD is smoking. BTW, the best seller for treating COPD, Advair Diskus (GSK), will be genericized by 2016.